A September 2026 report sets out a 1-for-3,000 reverse split of Can-Fite's ordinary shares in January 2026, and a change that cut each ADS from 300 ordinary shares to two. The company also lists the risk of failing NYSE American continued listing standards.
Can-Fite BioPharma's shelf sets a ceiling of $100,000,000, but the at-the-market sales agreement with H.C. Wainwright & Co., LLC covers only $1,065,000, a limit set by its public float.
Latest balance sheet, Dec 31, 2025 (20-F): cash and equivalents $5.5 million, plus short-term investments of $1,000, $5.5 million in all.
Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.
Questions about Can-Fite BioPharma
Did Can-Fite BioPharma do a reverse stock split?
Our latest story on this, dated Sep 8, 2026: "Can-Fite details 1-for-3,000 reverse split and ADS ratio change in 6-K". The story links the filing or release it is based on. Read the story.
Has Can-Fite BioPharma raised money recently?
Our latest story on this, dated Aug 28, 2026: "Can-Fite files $100,000,000 shelf with at-the-market program of up to $1,065,000". The story links the filing or release it is based on. Read the story.
What is the ticker symbol of Can-Fite BioPharma?
Can-Fite BioPharma Ltd. trades under the ticker CANF on TASE.
Where is Can-Fite BioPharma listed?
Can-Fite BioPharma Ltd. is listed on TASE. Our directory also records these other listings: AMEX:CANF.
What is the SEC CIK of Can-Fite BioPharma?
The SEC Central Index Key (CIK) for Can-Fite BioPharma Ltd. is 1536196. Its filings are on SEC EDGAR.
How many shares does Can-Fite BioPharma have outstanding?
2,618,425 shares as of 2025-12-31, per the cover page of its 20-F filed 2026-03-26.
Which country or territory is Can-Fite BioPharma listed under?
Our directory records Can-Fite BioPharma Ltd. under Israel.
What does Can-Fite BioPharma do?
Our directory classifies Can-Fite BioPharma Ltd. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
What is the ISIN of Can-Fite BioPharma?
The ISIN recorded for Can-Fite BioPharma Ltd. is IL0010944739.
Does aibio.space cover Can-Fite BioPharma?
aibio.space lists Can-Fite BioPharma Ltd. among 2,820 public biotech companies and publishes its news here as stories appear.
Where is Can-Fite BioPharma incorporated?
SEC records list its state or country of incorporation as L3.
What was Can-Fite BioPharma's revenue last year?
$405,000 for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Is Can-Fite BioPharma profitable?
Can-Fite BioPharma Ltd. reported a net loss of $9.8 million for the fiscal year ended Dec 31, 2025, and used $8.9 million of cash in operations, per its annual report to the SEC.
How much does Can-Fite BioPharma spend on research and development?
$6.7 million in the fiscal year ended Dec 31, 2025, per its annual report.
How much cash does Can-Fite BioPharma have?
$5.5 million in cash and short-term investments at Dec 31, 2025, per its 20-F.
Investor discussion: Can-Fite BioPharma
Members talk about Can-Fite BioPharma (CANF). Reader posts, not aibio.space reporting, and not investment advice.
Rules
Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
Say whether you hold the stock. Every post states long, short or no position.
No paid or sponsored posts. Do not post for anyone who pays or rewards you.
No buy or sell calls and no price targets.
No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
No personal details and no spam. No links at all for your first 7 days as a member.
Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.
Capital-markets timeline
Financings, listing notices, splits, legal actions and other investor events at Can-Fite BioPharma, newest first. Each line links the filing it comes from.
Listings
Reported a reverse stock split. SEC Form 6-K. Source
Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open TASE:CANF on TradingView.
SEC filings and registration
SEC name
Can-Fite BioPharma Ltd.
CIK
1536196
Industry (SIC)
Pharmaceutical Preparations (2834)
US tickers
CANF (NYSE)
State or country of incorporation
L3
Fiscal year ends
December 31
Filer category
Non-accelerated filer
Business address
26 BEN GURION STREET, RAMAT GAN, Israel, 5257346
Phone
972 39241114
Shares outstanding
2,618,425 as of 2025-12-31 (20-F filed 2026-03-26)
Recent filings (8-K and 6-K are the company's own announcements)
Source: SEC EDGAR, retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.
Listing details
Can-Fite BioPharma Ltd. is a public biotech or pharmaceutical company listed on TASE under the ticker CANF, recorded under Israel. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.
Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.
Published and maintained by aibio.space. Not investment advice. How we work.
Who manages this pageThis page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio